Literature DB >> 9356559

PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia.

S Kapur1, R Zipursky, G Remington, C Jones, G McKay, S Houle.   

Abstract

OBJECTIVE: Loxapine, a dibenzoxazepine antipsychotic, is closely related to clozapine and shares clozapine's high affinity for binding to serotonin 5-HT2 and dopamine D4 receptors. The purpose of this study was to document loxapine's 5-HT2 and D2 receptor occupancy in vivo in patients with psychoses.
METHOD: Ten patients who were taking loxapine (10-100 mg/day) had their D2 and 5-HT2 receptors assessed by means of positron emission tomography with [11C]raclopride and [18F]setoperone, respectively.
RESULTS: The D2 receptor occupancy ranged from 43% to 90%; 5-HT2 occupancy varied from 27% to near saturation. Statistical comparison of the results showed that loxapine was equipotent in blocking 5-HT2 and D2 receptors.
CONCLUSIONS: Loxapine differs from typical neuroleptics in demonstrating a high degree of 5-HT2 receptor occupancy. However, it is not "atypical" like clozapine and risperidone, since its 5-HT2 occupancy is not higher than its D2 occupancy. The results demonstrate that a high level of 5-HT2 occupancy is not a sufficient condition for atypicality. If atypical antipsychotic action is predicated on a combination of 5-HT2 and D2 effects, then it requires > 80% 5-HT2 occupancy in conjunction with < 80% D2 occupancy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9356559     DOI: 10.1176/ajp.154.11.1525

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  19 in total

Review 1.  Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics.

Authors:  E Stip
Journal:  J Psychiatry Neurosci       Date:  2000-03       Impact factor: 6.186

Review 2.  Understanding antipsychotic "atypicality": a clinical and pharmacological moving target.

Authors:  Gary Remington
Journal:  J Psychiatry Neurosci       Date:  2003-07       Impact factor: 6.186

3.  Modelling schizophrenia using human induced pluripotent stem cells.

Authors:  Kristen J Brennand; Anthony Simone; Jessica Jou; Chelsea Gelboin-Burkhart; Ngoc Tran; Sarah Sangar; Yan Li; Yangling Mu; Gong Chen; Diana Yu; Shane McCarthy; Jonathan Sebat; Fred H Gage
Journal:  Nature       Date:  2011-04-13       Impact factor: 49.962

4.  Loxapine add-on for adolescents and adults with autism spectrum disorders and irritability.

Authors:  Jessica A Hellings; Gregory Reed; Sharon E Cain; Xinghua Zhou; Francis X Barth; Michael G Aman; Gladys I Palaguachi; Dmytro Mikhnev; Rujia Teng; Rebecca Andridge; Marilyn Logan; Merlin G Butler; Joan C Han
Journal:  J Child Adolesc Psychopharmacol       Date:  2015-03       Impact factor: 2.576

Review 5.  First- and second-generation antipsychotic medication and cognitive processing in schizophrenia.

Authors:  Thomas W Weickert; Terry E Goldberg
Journal:  Curr Psychiatry Rep       Date:  2005-08       Impact factor: 5.285

Review 6.  Conventional versus novel antipsychotics: changing concepts and clinical implications.

Authors:  G Remington; S A Chong
Journal:  J Psychiatry Neurosci       Date:  1999-11       Impact factor: 6.186

Review 7.  Loxapine inhalation powder: a review of its use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia.

Authors:  Gillian M Keating
Journal:  CNS Drugs       Date:  2013-06       Impact factor: 5.749

Review 8.  Atypical neuroleptics in child and adolescent psychiatry.

Authors:  H Remschmidt; K Hennighausen; H W Clement; P Heiser; E Schulz
Journal:  Eur Child Adolesc Psychiatry       Date:  2000       Impact factor: 4.785

9.  A comparison of the effects of loxapine with ziprasidone and thioridazine on the release of dopamine and acetylcholine in the prefrontal cortex and nucleus accumbens.

Authors:  Zhu Li; Junji Ichikawa; Herbert Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  2003-03-28       Impact factor: 4.530

10.  Effect of loxapine on peripheral dopamine-like and serotonin receptors in patients with schizophrenia.

Authors:  Amarendra N Singh; Cia Barlas; Huma Saeedi; Ram K Mishra
Journal:  J Psychiatry Neurosci       Date:  2003-01       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.